{"url_path":"/sec/eikn/8-k/2026-06-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1861123/0001193125-26-249725-index.html","accession_number":"0001193125-26-249725","cik":"0001861123","ticker":"EIKN","issuer_name":"Eikon Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1861123/0001193125-26-249725-index.html","primary_entity_key":"0001861123","primary_entity_name":"Eikon Therapeutics, Inc."},"word_count":90,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n99.1\n\n \n\n[Eikon Therapeutics, Inc. Corporate Presentation as of May 30, 2026.](eikn-ex99_1.htm)\n\n99.2\n\n \n\n[Press Release dated May 30, 2026.](eikn-ex99_2.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nEIKON THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 1, 2026\n\nBy:\n\n/s/ Alfred Bowie, Ph.D.\n\n \n\n \n\n \n\nAlfred Bowie, Ph.D.\nChief Financial Officer"}